Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development
Reference number: GID-TA10994
Expected publication date: TBC
For information, NICE has decided to pause the single technology appraisal of rozanolixizumab for treatment of antibody-positive generalised myasthenia gravis. This is due to operational implications of an appeal for a single technology appraisal for another product being assessed for generalised myasthenia gravis. The appeal outcome will likely be known in late June.